InvestorsObserver
×
News Home

Is Harpoon Therapeutics Inc (HARP) a Leader in the Biotechnology Industry?

Thursday, February 22, 2024 02:10 PM | InvestorsObserver Analysts

Mentioned in this article

Is Harpoon Therapeutics Inc (HARP) a Leader in the Biotechnology Industry?

The 63 rating InvestorsObserver gives to Harpoon Therapeutics Inc (HARP) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 74 percent of stocks in the Biotechnology industry, HARP’s 63 overall rating means the stock scores better than 63 percent of all stocks.

Overall Score - 63
HARP has an Overall Score of 63. Find out what this means to you and get the rest of the rankings on HARP!

What do These Ratings Mean?

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as “good” for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 63 means the stock is more attractive than 63 percent of stocks.
This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

What's Happening With Harpoon Therapeutics Inc Stock Today?

Harpoon Therapeutics Inc (HARP) stock is trading at $22.96 as of 2:10 PM on Thursday, Feb 22, an increase of $0.33, or 1.48% from the previous closing price of $22.62. Volume today is above average. So far 4,968,908 shares have traded compared to average volume of 1,286,599 shares. The stock has traded between $22.93 and $22.96 so far today. Click Here to get the full Stock Report for Harpoon Therapeutics Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App